2-methyl-1,2,3,4-tetrahydroisoquinolin-4-ol | 84087-59-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-methyl-1,2,3,4-tetrahydroisoquinolin-4-ol
• 英文别名: 2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-ol；2-Methyl-1,2,3,4-tetrahydro-isochinolin-4-ol；1,2,3,4-tetrahydro-2-methyl-4-isoquinolinol；2-Methyl-1,2,3,4-tetrahydro-4-isoquinolinol；2-methyl-3,4-dihydro-1H-isoquinolin-4-ol
• CAS: 84087-59-2
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: WKXFPPWKGPJVEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-1,2,3,4-tetrahydroisoquinolin-4-ol 在 碘 、 叔丁基锂 作用下， 生成 1,2,3,4-tetrahydro-5-iodo-2-methylisoquinolin-4-ol
  参考文献：
  名称：

  Three complementary methods offering access to 5-substituted 1,2,3,4-tetrahydroisoquinolines

  摘要：

  The scope and limitations of three independent though related routes leading to 5-substituted tetrahydroisoquinolines are explored : the Pidet-Spengler type cyclization of ortho-substituted 2-phenylethylamines, the Pomeranz-Fritsch type cyclization of meta-substituted benzylamines and the electrophilic trapping of 5-lithiated 4-lithiooxytetrahydroquinolines. The introduction of the substituent relies in all three cases on a neighboring group assisted site selective metalation step. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(98)00541-9
• 作为产物：
  描述：

  2-methyl-4-oxo-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid ethyl ester 在 盐酸 、 lithium aluminium tetrahydride 、 乙醚 、 水 作用下， 生成 2-methyl-1,2,3,4-tetrahydroisoquinolin-4-ol
  参考文献：
  名称：

  121.环状酮胺。第四部分 1：2：3：4-四氢-2-甲基-4-氧代异喹啉的合成与反应

  摘要：

  DOI：

  10.1039/jr9590000599

文献信息

• [EN] DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS<br/>[FR] INHIBITEURS DOUBLES DE NAV1.2/5HT2A POUR TRAITER DES TROUBLES DU SNC
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2018026371A1

  公开（公告）日：2018-02-08

  Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  公开了化学式I的化合物，以及含有这些化合物的药物组合物。还公开了治疗患有神经系统或精神障碍的患者的方法。这些障碍包括抑郁症、躁郁症、疼痛、精神分裂症、强迫症、成瘾、社交障碍、注意力缺陷多动障碍、焦虑障碍、自闭症、认知障碍，或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及在神经系统疾病如阿尔茨海默病和帕金森病中的睡眠障碍。
• 4-Substituted N-methyl-1,2,3,4-tetrahydroisoquinolines: synthesis via stereoselective substitution of tricarbonyl(N-methyl-1,2,3,4-tetrahydroisoquinoline)chromium
  作者：Julian Blagg、Stephen G. Davies、Bryan E. Mobbs

  DOI：10.1039/c39850000619

  日期：——

  Tricarbonyl(N-methyl-1,2,3,4-tetrahydroisoquinolines)chromium undergoes stereoselective 4-exo-deprotonation and subsequent electrophilic additions to generate the corresponding 4-exo-derivatives which after decomplexation yield 4-alkyl-, 4-phenyl-, and 4-hydroxy-N-methyl-1,2,3,4- tetrahydroisoquinolines.

  三羰基（N-甲基-1,2,3,4-四氢异喹啉）铬经历立体选择性4-外-去质子化反应，随后进行亲电加成生成相应的4-外-外衍生物，在分解后生成4-烷基-，4-苯基-和4-羟基-N-甲基-1,2,3,4-四氢异喹啉。
• 4-Aryloxy-1,2,3,4-tetrahydroisoquinolines
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04375471A1

  公开（公告）日：1983-03-01

  This invention relates to 4-aryloxy-1,2,3,4-tetrahydroisoquinolines of the formula ##STR1## , where Y is hydrogen and alkoxy; X is hydrogen, cyano, benzoyl, trifluoromethyl, phenyl, halogen, alkyl alkoxy and nitro; R is hydrogen and alkyl; R.sub.1 is hydrogen, alkyl, aralkyl, ##STR2## and CO.sub.2 R.sub.4 where R.sub.4 is aryl and alkyl; R.sub.2 and R.sub.3 are the same or different and are hydrogen and alkyl or R.sub.2 and R.sub.3 are fused together to form a pyrrolidino or a piperidino ring substituent; and m is an integer of 1 or 2; n is an integer of 2 or 3; and a pharmaceutically acceptable acid addition salt thereof.

  这项发明涉及式子##STR1##的4-芳氧基-1,2,3,4-四氢异喹啉，其中Y是氢和烷氧基；X是氢、氰基、苯甲酰基、三氟甲基、苯基、卤素、烷基烷氧基和硝基；R是氢和烷基；R.sub.1是氢、烷基、芳基烷基、##STR2##和CO.sub.2 R.sub.4，其中R.sub.4是芳基和烷基；R.sub.2和R.sub.3相同或不同，是氢和烷基，或者R.sub.2和R.sub.3融合在一起形成吡咯啉或哌啶环取代基；m是1或2的整数；n是2或3的整数；以及其药学上可接受的酸盐。
• Methods of alleviating convulsions and pain employing 4-aryloxy-1,2,3,4
  申请人：Hoechst-Roussel Pharmaceuticals Incorporated

  公开号：US04551474A1

  公开（公告）日：1985-11-05

  This invention relates to 4-aryloxy-1,2,3,4-tetrahydroisoquinolines of the formula ##STR1## where Y is hydrogen and alkoxy; X is hydrogen, cyano, benzoyl, trifluoromethyl, phenyl, halogen, alkyl alkoxy and nitro; R is hydrogen and alkyl; R.sub.1 is hydrogen, alkyl, aralkyl, ##STR2## and CO.sub.2 R.sub.4 where R.sub.1 is aryl and alkyl; R.sub.2 and R.sub.3 are the same or differnt and are hydrogen and alkyl or R.sub.2 and R.sub.3 are fused together to form a pyrrolidino or a piperidino ring substituent; and m is an integer of 1 or 2; n is an integer of 2 or 3; and a pharmaceutically acceptable acid addition salt thereof.

  本发明涉及以下式子的4-芳氧基-1,2,3,4-四氢异喹啉：##STR1## 其中Y是氢和烷氧基；X是氢、氰、苯甲酰、三氟甲基、苯基、卤素、烷基烷氧基和硝基；R是氢和烷基；R.sub.1是氢、烷基、芳基烷基、##STR2## 和CO.sub.2 R.sub.4，其中R.sub.1是芳基和烷基；R.sub.2和R.sub.3相同或不同，是氢和烷基，或者R.sub.2和R.sub.3融合在一起形成吡咯啉或哌啶环取代基；m是1或2的整数；n是2或3的整数；以及其药学上可接受的酸加成盐。
• 4-Aryloxy-1,2,3,4-tetrahydroisoquinolines, and intermediates, a process for preparing the same, a pharmaceutical composition containing the same and their use as medicaments
  申请人：HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED

  公开号：EP0058932A2

  公开（公告）日：1982-09-01

  This invention relates to 4-aryloxy-1,2,3,4-tetrahydro- isoquinolines of the formula where Y is hydrogen and alkoxy; X is hydrogen, cyano, benzoyl, trifluoromethyl, phenyl, halogen, alkyl, alkoxy and nitro; R is hydrogen and alkyl; R, is hydrogen, alkyl, aralkyl, and CO2R4, where R4 is aryl and alkyl; R2 and R3 are the same or different and are hydrogen and alkyl or R2 and R3 are fused together to form a pyrrolidino or a piperidino ring substituent; and m is an integer of 1 or 2; n is an integer of 2 or 3; and a pharmaceutically acceptable acid addition salt thereof.

  本发明涉及 4-芳氧基-1,2,3,4-四氢-异喹啉，其式为 其中 Y 是氢和烷氧基；X 是氢、氰基、苯甲酰基、三氟甲基、苯基、卤素、烷基、烷氧基和硝基；R 是氢和烷基；R, 是氢、烷基、芳烷基、 和 CO2R4，其中 R4 是芳基和烷基；R2 和 R3 相同或不同，并且是氢和烷基或 R2 和 R3 融合在一起形成吡咯烷或哌啶环取代基；以及 m 是 1 或 2 的整数；n 是 2 或 3 的整数；及其药学上可接受的酸加成盐。